ERBB2 and breast carcinoma: These data suggest that AKT activation is not dependent on HER2 kinase activation in most urothelial cancer cells, including at least a subset of those with ERBB2 mutation, which contrasts with prior studies suggesting that breast cancers with HER2 amplification are selectively dependent on AKT signaling36.